Single-cell analysis of CML patients bone marrow at diagnosis reveals coexistence of CD26-CD35+ healthy stem cells and CD26+CD35- CML stem cells, and how the ratio between these impacts TKI response.

ICON’s novel RNA-based NGS assay, Dup-Seq BCR::ABL1, represents a significant advancement in the management of CML patients.

More than $994 million has been raised by Cambridge technology companies in the past 12 months (to October 16, 2024) – helped ...

The S&P/ASX 200 Information Technology sector fell 4.43% in October but leads ASX sectors YTD, up 41.95% Global X investment ...

Their work can help to lower the ... The Evolution of Green Energy Technology: Developing Three-Dimensional Smart Energy Devices With Radiant Cooling and Solar Absorption Oct. 25, 2024 — - DGIST ...

The technology accurately detects the presence of these gene fusions in acute promyelocytic leukemia (APL) and chronic myeloid leukemia (CML) in patient samples. Researchers at Dana-Farber Cancer ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Chuck Schumer says a semiconductor research facility in upstate New York will be getting $825 million in funding as one of three national technology centers Across the U.S., people's phones are ...

Novartis has received FDA accelerated approval for Scemblix (asciminib) to treat adults with newly diagnosed Ph+ CML-CP.

Today the battle over standards is between China and the West. At stake is the future of technologies ranging from wireless communication to quantum computing and artificial intelligence (AI).

The technology accurately detects the presence of these gene fusions in acute promyelocytic leukemia (APL) and chronic myeloid leukemia (CML) in patient samples. Precision medicines have long been ...